Appendix Table 6.

Factors Associated With Amount of VL in Adjusted Models That Also Included CD4 Cell Count at ART Initiation and Cohort Year Squared Among Patients Receiving ART^*

Covariate	Linear Mixed Models†
	Relative VL	95% CI	P Value	Relative VL	95% CI	P Value
Integrase strand transfer inhibitor use	0.71	0.68–0.73	<0.001	0.70	0.67–0.72	<0.001
Female	1.05	0.98–1.12	0.141	0.99	0.93–1.06	0.86
Age (per decade, centered at 40 y)	0.82	0.80–0.84	<0.001	0.83	0.81–0.85	<0.001
Race/ethnicity (reference is white race)
Black	1.41	1.33–1.50	<0.001	1.60	1.51–1.70	<0.001
Hispanic	0.77	0.71–0.83	<0.001	0.90	0.83–0.97	0.006
Other	0.81	0.73–0.90	<0.001	0.89	0.80–0.99	0.039
Calendar time (year of cohort entry, centered around 2010)	0.85	0.85–0.86	<0.001	0.88	0.87–0.89	<0.001
Years of follow-up	0.75	0.74–0.75	<0.001	0.75	0.74–0.75	<0.001
CD4 count at ART initiation (per 0.100 × 109 cells/L)	0.83	0.82–0.84	<0.001	-	-	-
Cohort entry year squared (from 2010)	-	-	-	1.01	1.00–1.01	<0.001

ART = antiretroviral therapy; VL = viral load.

^*Also adjusted for site.

^†Outcome is VL in log₁₀ copies/mL.